A nationwide population-based study on the incidence and prognosis of HER2-positive breast cancer eligible for adjuvant pertuzumab in the modern era of neoadjuvant therapy
Author:
Antonis Valachis,Xingrong Liu,Balazs Acs,Johan Hartman,Theodoros Foukakis,Alexios Matikas
Date:
Available online 8 June 2026
© 2026 The Authors. Published by Elsevier Ltd.